Is AstraZeneca PLC Stock a Good Investment?
AstraZeneca PLC Investment Advice | AZN |
- Examine AstraZeneca PLC's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AstraZeneca PLC's leadership team and their track record. Good management can help AstraZeneca PLC navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact AstraZeneca PLC's business and its evolving consumer preferences.
- Compare AstraZeneca PLC's performance and market position to its competitors. Analyze how AstraZeneca PLC is positioned in terms of product offerings, innovation, and market share.
- Check if AstraZeneca PLC pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AstraZeneca PLC's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AstraZeneca PLC ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AstraZeneca PLC ADR is a good investment.
Sell | Buy |
Sell
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine AstraZeneca PLC Stock
Researching AstraZeneca PLC's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.9. AstraZeneca PLC ADR last dividend was issued on the 9th of August 2024. The entity had 2:1 split on the 27th of July 2015.
To determine if AstraZeneca PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AstraZeneca PLC's research are outlined below:
| AstraZeneca PLC ADR has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return. | |
| AstraZeneca PLC ADR has a very strong financial position based on the latest SEC filings | |
| On 9th of September 2024 AstraZeneca PLC paid $ 0.5 per share dividend to its current shareholders | |
| Latest headline from channelnewsasia.com: AI in Southeast Asia Innovation revolutionises healthcare but experts diagnose a need for greater trust in new tech |
AstraZeneca PLC Quarterly Liabilities And Stockholders Equity |
|
AstraZeneca PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AstraZeneca PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AstraZeneca PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact AstraZeneca PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises AstraZeneca PLC's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2002-10-24 | 2002-09-30 | 0.18 | 0.2 | 0.02 | 11 | ||
1999-10-29 | 1999-09-30 | 0.17 | 0.19 | 0.02 | 11 | ||
2005-04-28 | 2005-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2004-04-29 | 2004-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2003-07-24 | 2003-06-30 | 0.17 | 0.2 | 0.03 | 17 | ||
2001-10-24 | 2001-09-30 | 0.21 | 0.24 | 0.03 | 14 | ||
2002-04-26 | 2002-03-31 | 0.24 | 0.28 | 0.04 | 16 | ||
2000-10-25 | 2000-09-30 | 0.23 | 0.19 | -0.04 | 17 |
AstraZeneca PLC Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AstraZeneca target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. AstraZeneca PLC's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most AstraZeneca analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand AstraZeneca stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of AstraZeneca PLC ADR, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAstraZeneca PLC Target Price Projection
AstraZeneca PLC's current and average target prices are 79.16 and 83.71, respectively. The current price of AstraZeneca PLC is the price at which AstraZeneca PLC ADR is currently trading. On the other hand, AstraZeneca PLC's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
AstraZeneca PLC Market Quote on 12th of September 2024
Target Price
Analyst Consensus On AstraZeneca PLC Target Price
AstraZeneca PLC Analyst Ratings
AstraZeneca PLC's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about AstraZeneca PLC stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of AstraZeneca PLC's financials, market performance, and future outlook by experienced professionals. AstraZeneca PLC's historical ratings below, therefore, can serve as a valuable tool for investors.Know AstraZeneca PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AstraZeneca PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AstraZeneca PLC ADR backward and forwards among themselves. AstraZeneca PLC's institutional investor refers to the entity that pools money to purchase AstraZeneca PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fisher Asset Management, Llc | 2024-06-30 | 10 M | Atlantic Trust Group, Llc | 2024-06-30 | 9.2 M | Blackrock Inc | 2024-06-30 | 7 M | Capital World Investors | 2024-06-30 | 6.3 M | Neuberger Berman Group Llc | 2024-06-30 | 5.4 M | Ameriprise Financial Inc | 2024-06-30 | 4.9 M | Dimensional Fund Advisors, Inc. | 2024-06-30 | 4.4 M | Wcm Investment Management | 2024-06-30 | 4 M | Jpmorgan Chase & Co | 2024-03-31 | 4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 64.9 M | Primecap Management Company | 2024-06-30 | 42.6 M |
AstraZeneca PLC's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 251.38 B.Market Cap |
|
AstraZeneca PLC's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.11 | |
| Return On Capital Employed | 0.12 | 0.11 | |
| Return On Assets | 0.06 | 0.10 | |
| Return On Equity | 0.15 | 0.14 |
Determining AstraZeneca PLC's profitability involves analyzing its financial statements and using various financial metrics to determine if AstraZeneca PLC is a good buy. For example, gross profit margin measures AstraZeneca PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AstraZeneca PLC's profitability and make more informed investment decisions.
Evaluate AstraZeneca PLC's management efficiency
AstraZeneca PLC ADR has Return on Asset of 0.0768 % which means that on every $100 spent on assets, it made $0.0768 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1674 %, implying that it generated $0.1674 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of September 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Return On Assets are very stable compared to the past year. As of the 12th of September 2024, Asset Turnover is likely to grow to 0.79, while Total Current Assets are likely to drop about 15.3 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 12.64 | 13.27 | |
| Tangible Book Value Per Share | (6.12) | (5.82) | |
| Enterprise Value Over EBITDA | 16.64 | 9.83 | |
| Price Book Value Ratio | 5.33 | 9.53 | |
| Enterprise Value Multiple | 16.64 | 9.83 | |
| Price Fair Value | 5.33 | 9.53 | |
| Enterprise Value | 208.3 B | 218.7 B |
The analysis of AstraZeneca PLC's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze AstraZeneca PLC's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of AstraZeneca Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.0184 | Forward Dividend Yield 0.0184 | Forward Dividend Rate 1.49 | Beta 0.167 |
Basic technical analysis of AstraZeneca Stock
As of the 12th of September 2024, AstraZeneca PLC shows the Downside Deviation of 1.37, risk adjusted performance of 0.0207, and Mean Deviation of 0.8367. AstraZeneca PLC ADR technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.AstraZeneca PLC's Outstanding Corporate Bonds
AstraZeneca PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AstraZeneca PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AstraZeneca bonds can be classified according to their maturity, which is the date when AstraZeneca PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ASTRAZENECA PLC 645 Corp BondUS046353AD01 | View | |
| ASTRAZENECA PLC 3375 Corp BondUS046353AL27 | View | |
| ASTRAZENECA PLC 4375 Corp BondUS046353AM00 | View | |
| ASTRAZENECA PLC 4 Corp BondUS046353AG32 | View | |
| ASTRAZENECA PLC 4 Corp BondUS046353AT52 | View | |
| ASTRAZENECA PLC 4375 Corp BondUS046353AU26 | View | |
| ASTRAZENECA PLC 3125 Corp BondUS046353AN82 | View | |
| ASTRAZENECA PLC Corp BondUS046353AV09 | View |
Understand AstraZeneca PLC's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AstraZeneca PLC's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0207 | |||
| Market Risk Adjusted Performance | 0.0536 | |||
| Mean Deviation | 0.8367 | |||
| Semi Deviation | 1.31 | |||
| Downside Deviation | 1.37 | |||
| Coefficient Of Variation | 4479.62 | |||
| Standard Deviation | 1.13 | |||
| Variance | 1.28 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.0436 | |||
| Maximum Drawdown | 5.79 | |||
| Value At Risk | (2.17) | |||
| Potential Upside | 1.64 | |||
| Downside Variance | 1.87 | |||
| Semi Variance | 1.71 | |||
| Expected Short fall | (0.75) | |||
| Skewness | (0.71) | |||
| Kurtosis | 0.9642 |
| Risk Adjusted Performance | 0.0207 | |||
| Market Risk Adjusted Performance | 0.0536 | |||
| Mean Deviation | 0.8367 | |||
| Semi Deviation | 1.31 | |||
| Downside Deviation | 1.37 | |||
| Coefficient Of Variation | 4479.62 | |||
| Standard Deviation | 1.13 | |||
| Variance | 1.28 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.0436 | |||
| Maximum Drawdown | 5.79 | |||
| Value At Risk | (2.17) | |||
| Potential Upside | 1.64 | |||
| Downside Variance | 1.87 | |||
| Semi Variance | 1.71 | |||
| Expected Short fall | (0.75) | |||
| Skewness | (0.71) | |||
| Kurtosis | 0.9642 |
Consider AstraZeneca PLC's intraday indicators
AstraZeneca PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AstraZeneca PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AstraZeneca PLC Corporate Filings
6K | 3rd of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 26th of June 2024 Other Reports | ViewVerify | |
| 4th of June 2024 Other Reports | ViewVerify |
AstraZeneca Stock media impact
Far too much social signal, news, headlines, and media speculation about AstraZeneca PLC that are available to investors today. That information is available publicly through AstraZeneca media outlets and privately through word of mouth or via AstraZeneca internal channels. However, regardless of the origin, that massive amount of AstraZeneca data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AstraZeneca PLC news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AstraZeneca PLC relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AstraZeneca PLC's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AstraZeneca PLC alpha.
AstraZeneca PLC ADR Historical Investor Sentiment
Investor biases related to AstraZeneca PLC's public news can be used to forecast risks associated with an investment in AstraZeneca. The trend in average sentiment can be used to explain how an investor holding AstraZeneca can time the market purely based on public headlines and social activities around AstraZeneca PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AstraZeneca PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AstraZeneca PLC and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average AstraZeneca PLC news discussions. The higher the estimate score, the more favorable the investor's outlook on AstraZeneca PLC.
AstraZeneca PLC Maximum Pain Price across 2024-09-13 Option Contracts
AstraZeneca PLC's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of AstraZeneca PLC close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of AstraZeneca PLC's options.
AstraZeneca PLC Corporate Directors
| Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
| Sherilyn McCoy | Non-Executive Independent Director | Profile | |
| Genevieve Berger | Non-Executive Independent Director | Profile | |
| Nazneen Rahman | Non-Executive Independent Director | Profile |
Already Invested in AstraZeneca PLC ADR?
The danger of trading AstraZeneca PLC ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AstraZeneca PLC is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AstraZeneca PLC. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AstraZeneca PLC ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in AstraZeneca Stock
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.06 | Dividend Share 2.97 | Earnings Share 2.06 | Revenue Per Share 2.6327 | Quarterly Revenue Growth 0.133 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between AstraZeneca PLC's value and its price, as these two are different measures arrived at by various means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.